BoneDiscover Updates in New and Emerging Therapies

Sessions, journal articles, and point of care tools highlight the molecular discoveries and evolving treatment options for rare metabolic bone diseases and osteoporosis in patients of all ages.

Menopausal Hormone Therapy Improves Bone Health
November 17, 2016 | Study reveals bone density, structure benefits persist after treatment ends. Women who undergo hormone therapy for menopausal symptoms such as hot flashes can not only increase…

Customized Vitamin D Supplements May Benefit Pregnant Women
October 27, 2016 | Doses can be tailored to compensate for individual risk factors, protect bone health. Individualized supplement doses help protect pregnant women from vitamin D deficiency, according…

Chemical Exposure Linked to Lower Vitamin D Levels
September 20, 2016 | Endocrine-disrupting chemicals may alter active form of vitamin in body. Exposure to bisphenol A (BPA) and other endocrine-disrupting chemicals (EDCs) may reduce levels of vitamin D…

Case-Based Update on Hypoparathyroidism
CEU Satellite Symposium | 2.0 AMA PRA Category 1 Credits™
Chair: Steven T. Harris, MD
Faculty: Susan M. Ott, MD; Lynn A. Kohlmeier, MD; and Nelson B. Watts, MD
Weigh the traditional and contemporary treatment options with discussions on diagnostic and etiology.

Hypoparathyroidism @Point of Care
Practice Resource | No credit available
Find practical information when you need it the most to recognize signs, interpret results, and guide treatment decisions.

Hypophosphatasia: New Options in the Management of Alkaline Phosphatase Deficiency
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™ and ABIM MOC Part 2 points
Chair: Jill H. Simmons, MD
Faculty: Nancy S. Dunbar, MD, MPH; Peter J. Tebben, MD; and Michael P. Whyte, MD
What does low alkaline phosphatase mean in practice? Recognize subtle signs of HPP in pediatric and adult patients and learn about the most recent treatment approvals.

New Frontiers in Osteoporosis: Targets in Bone Remodeling
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™ and ABIM MOC Part 2 points
Chair: Michael R. McClung, MD
Faculty: Paul D. Miller, MD; Bente Lomholt Langdahl, PhD, DMSc; and Benjamin Zev Leder, MD
Keep up to date on the latest trials and emerging treatments in this rapidly evolving field.

Bone Health Digital Toolkit
Patient Resource | No credit available
Reviewer: Ramon E. Martinez, MD
Check out interactive and downloadable resources and information for patients with questions about maintaining bone health and disease.

Endocrine Facts & Figures: Bone and Mineral
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on disorders of bone and mineral metabolism with current citations and expert insights.

Primary Aldosteronism as a Risk Factor for Vertebral Fracture
JCEM | February 09, 2017
Masakazu Notsu, Mika Yamauchi, Masahiro Yamamoto, Kiyoko Nawata,and Toshitsugu Sugimoto
Some observational studies have revealed an association between excessive aldosterone levels and reduced bone mineral density…

Influence of Premature Mortality on the Link Between Type 2 Diabetes and Hip Fracture: The Fremantle Diabetes Study
JCEM | November 23, 2016
Emma Hamilton, Wendy A. Davis, David G. Bruce, and Timothy M. E. Davis
There is consistent evidence that type 2 diabetes is associated with an increased incidence of hip fracture…

Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation during Pregnancy
JCEM | October 28, 2016
Rebecca J. Moon, Nicholas C. Harvey, Cyrus Cooper, Stefania D'Angelo, Sarah R. Crozier, Hazel M. Inskip, Inez Schoenmakers, Ann Prentice, Nigel K. Arden, Nicholas J. Bishop, Andrew Carr, Elaine M. Dennison, Richard Eastell, Robert Fraser, Saurabh V. Gandhi, Keith M. Godfrey, Stephen Kennedy, M. Zulf Mughal, Aris T. Papageorghiou, David M. Reid, Sian M. Robinson, and M. Kassim Javaid
Context: Current approaches to antenatal vitamin D supplementation do not account for interindividual differences in 25-hydroxyvitamin D (25(OH)D) response. Objective: We assessed which maternal and…

Genetic Variants in the Vitamin D Pathway, 25(OH)D Levels, and Mortality in a Large Population-Based Cohort Study
JCEM | October 12, 2016
José Manuel, Ordóñez-Mena, Haifa Maalmi, Ben Schöttker, Kai-Uwe Saum, Bernd Holleczek, Thomas J. Wang, Barbara Burwinkel, and Hermann Brenner
Over the last 10 years, several epidemiological studies have suggested that low vitamin D status influences the risk…

Stress Fractures: Concepts and Therapeutics
JCEM | October 12, 2016
Carolina A. Moreira and John P. Bilezikian
When bones are stressed beyond the limit of their capacity to bear a mechanical load, fractures result. This imbalance…

Intraoperative Real-Time Localization of Normal Parathyroid Glands with Autofluorescence Imaging
JCEM | September 20, 2016
Sung Won Kim, Seo Hyun Song, Hyoung Shin Lee, Woong Jae Noh, Chulho Oak, Yeh-Chan Ahn, and Kang Dae Lee
Context: This biomedical investigation is valuable for identification and localization of parathyroid glands during thyroidectomy, which can provide an intraoperative real-time visual guidance. Objective: The…

Hormone Replacement Therapy versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density
JCEM | June 24, 2016
Beth Cartwright, Jillian Robinson, Paul T. Seed, Ignac Fogelman and Janice Rymer
Context: Women with premature ovarian failure (POF) face many years of estrogen deficiency. One of the major consequences is bone loss. The optimal form of estrogen replacement…

Quantifying the Balance between Total Bone Formation and Total Bone Resorption: An Index of Net Bone Formation
JCEM | June 23, 2016
Albert Shieh, Weijuan Han, Shinya Ishii, Gail A. Greendale, Carolyn J. Crandall and Arun S. Karlamangla
Context: Bone gain vs loss across the skeleton loss depends on the balance between total bone formation and total bone resorption. Objective: The objective of the study…

Denosumab or Zoledronic Acid in Postmenopausal Women with Osteoporosis Previously Treated With Oral Bisphosphonates
JCEM | June 6, 2016
P. D. Miller, N. Pannacciulli, J. P. Brown, E. Czerwinski, B. S. Nedergaard, M. A. Bolognese, J. Malouf, H. G. Bone, J.-Y. Reginster, A. Singer, C. Wang, R. B. Wagman and S. R. Cummings
Context: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. Objective: The objective of the study was to compare the effect of transitioning…

Complex Genomic Rearrangement Within the GNAS Region Associated With Familial Pseudohypoparathyroidism Type 1b
JCEM | June 2, 2016
Akie Nakamura, Erika Hamaguchi, Reiko Horikawa, Yasuyuki Nishimura, Keiko Matsubara, Shinichiro Sano, Keisuke Nagasaki, Yoichi Matsubara, Akihiro Umezawa, Toshihiro Tajima, Tsutomu Ogata, Masayo Kagami, Kohji Okamura and Maki Fukami
Context: Pseudohypoparathyroidism type 1b (PHP-1b) results from methylation defects at the G protein stimulatory α subunit (GNAS) exon A/B-differentially methylated region (DMR). Although microduplications in…

Paget's Disease of Bone
JCEM | November 19, 2014
Frederick R. Singer, Henry G. Bone III, David J. Hosking, Kenneth W. Lyles, Mohammad Hassan Murad, Ian R. Reid, and Ethel S. Siris
We recommend that plain radiographs be obtained of the pertinent regions of the skeleton in patients with suspected Paget's disease. If the diagnosis is confirmed…

Osteoporosis in Men
JCEM | July 02, 2013
Nelson B. Watts, Robert A. Adler, John P. Bilezikian, Matthew T. Drake, Richard Eastell, Eric S. Orwoll, and Joel S. Finkelstein
Osteoporosis in men causes significant morbidity and mortality. We recommend testing higher risk men [aged ≥70 and men aged 50–69 who have risk factors…

Evaluation, Treatment, and Prevention of Vitamin D Deficiency
JCEM | June 06, 2011
Michael F. Holick, Neil C. Binkley, Heike A. Bischoff-Ferrari, Catherine M. Gordon, David A. Hanley, Robert P. Heaney, M. Hassan Murad, and Connie M. Weaver
Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at…

World Congress on Osteoporosis Osteoarthritis and Musculoskeletal Diseases 2017
Dates: March 23 - 26, 2017
Location: Florence, Italy
Sponsor: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and International Osteoporosis Foundation (IOF)

8th International Conference on Children's Bone Health
Dates: June 10 - 13, 2017
Location: Würzburg, Germany

Endocrine Fellows Series: Osteoporosis and Metabolic Bone Diseases
Sponsor: ICCBH 
Dates: August 2 - 3, 2017
Location: Santa Fe, New Mexico, United States
Sponsor: Endocrine Society

American Society for Bone and Mineral Research 2017 Annual Meeting
Dates: September 8 - 11, 2017
Location: Colorado Convention Center, Denver, Colorado, United States
Sponsor: American Society for Bone and Mineral Research

27th International Conference on Osteoporosis
Dates: December 4-5, 2017
Sponsor: Pulsus Group
Location: Madrid, Spain

World Congress on Osteoporosis Osteoarthritis and Musculoskeletal Diseases
Dates: April 19-22, 2018
Sponsor: European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and International Osteoporosis Foundation (IOF)
Location: Krakow, Poland

Popular Resources